Xiaoqiang Qian1, Xiangjie Kong1, Yu Qian2, Ding Xu1, Hailong Liu1, Yunkai Zhu3, Wenbing Guan4, Junhua Zheng5, Zhong Wang6, Jun Qi1. 1. Department of Urology, Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China. 2. Department of Urology, Shanghai Kongjiang Hospital Shanghai, China. 3. Department of Ultrasound in Medicine, Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China. 4. Department of Pathology, Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China. 5. Department of Urology, Affiliated Tenth People's Hospital of Shanghai Tongji University School of Medicine Shanghai, China. 6. Department of Urology, Affiliated Ninth People's Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China.
Abstract
OBJECTIVE: This study was to prospectively evaluate the therapeutic efficacy of Cernilton in benign prostatic hyperplasia (BPH) patients with histological prostatitis after transurethral resection of the prostate (TURP). MATERIALS AND METHODS: One hundred patients with histological prostatitis were recruited from January 2007 to January 2013. All patients were divided into groups A (mild), B (moderate), and C (severe) based on symptom severity, and then randomly subgrouped into Cernilton group and control group. Patients in Cernilton group were treated with Cernilton for 3 months after TURP, while patients in control group received placebo. A series of patient indicators were evaluated before, perioperatively (peri), and after TURP. RESULTS: The assessed indicators remained unchanged peri-TURP as compared to those before surgery. 6 months after TURP, indicators remained stable in group A, and significant differences were observed in the International Index of Erectile Function-5 (IIEF-5) in group B and in the storage symptom score (Ss), quality of life (QoL) and IEFF-5 in group C. In addition, there were significant differences in Ss, QoL and IEFF-5 between Cernilton group and control group. CONCLUSION: In BPH patients with histological prostatitis after TURP, Cernilton can improve the lower urinary tract symptoms and sexual dysfunction depending on the grade of prostatitis.
RCT Entities:
OBJECTIVE: This study was to prospectively evaluate the therapeutic efficacy of Cernilton in benign prostatic hyperplasia (BPH) patients with histological prostatitis after transurethral resection of the prostate (TURP). MATERIALS AND METHODS: One hundred patients with histological prostatitis were recruited from January 2007 to January 2013. All patients were divided into groups A (mild), B (moderate), and C (severe) based on symptom severity, and then randomly subgrouped into Cernilton group and control group. Patients in Cernilton group were treated with Cernilton for 3 months after TURP, while patients in control group received placebo. A series of patient indicators were evaluated before, perioperatively (peri), and after TURP. RESULTS: The assessed indicators remained unchanged peri-TURP as compared to those before surgery. 6 months after TURP, indicators remained stable in group A, and significant differences were observed in the International Index of Erectile Function-5 (IIEF-5) in group B and in the storage symptom score (Ss), quality of life (QoL) and IEFF-5 in group C. In addition, there were significant differences in Ss, QoL and IEFF-5 between Cernilton group and control group. CONCLUSION: In BPH patients with histological prostatitis after TURP, Cernilton can improve the lower urinary tract symptoms and sexual dysfunction depending on the grade of prostatitis.
Entities:
Keywords:
Prostatic hyperplasia; cernilton; histological prostatitis; transurethral resection of prostate
Authors: Vibhash C Mishra; Darrell J Allen; Christophoros Nicolaou; Haytham Sharif; Charles Hudd; Omer M A Karim; Hanif G Motiwala; Marc E Laniado Journal: BJU Int Date: 2007-08 Impact factor: 5.588
Authors: Florian M E Wagenlehner; Henning Schneider; Martin Ludwig; Jörg Schnitker; Elmar Brähler; Wolfgang Weidner Journal: Eur Urol Date: 2009-06-03 Impact factor: 20.096